SK Bioscience to license in Novavax' COVID-19 vaccine
President Moon Jae-in poses with SK Group Chairman Chey Tae-won, left, during a visit to SK Bioscience's plant in Andong, North Gyeongsang Province, Wednesday. Yonhap'Vaccines for 20 mil. people likely be secured,' says Moon By Nam Hyun-wooPresident Moon Jae-in visited SK Bioscience's plant in Andong, North Gyeongsang Province, Wednesday, which is contract manufacturing the U.S.-based Novavax's COVID-19 vaccine. The visit comes a year to the day that Korea reported its first case of the coronavirus disease, and followed a video conference the President had with Novavax CEO Stanley Erck. During their talks Moon discussed ways to improve the supply of the vaccine to Korea via an in-licensing deal for SK Bioscience.As a contract manufacturer SK Bioscience produces vaccines for Novavax; as an in-licensing partner it can market the product, and also use production technology to develop its own vaccines. “After securing COVID-19 vaccines for 56 million people so far, chances are high for us to add more for 20 million people as SK Bioscience and Novavax have been preparing an in-licen
Jan 20, 2021By Nam Hyun-woo